ALX Oncology
ALXO
61 hedge funds and large institutions have $12.6M invested in ALX Oncology in 2025 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 32 reducing their positions, and 34 closing their positions.
586% more call options, than puts
Call options by funds: $48K | Put options by funds: $7K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10.75% less ownership
Funds ownership: 65.2% → 54.45% (-11%)
28% less funds holding
Funds holding: 85 → 61 (-24)
43% less capital invested
Capital invested by funds: $22.1M → $12.6M (-$9.55M)
71% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 34
72% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Almitas Capital
Santa Monica,
California
|
+$598K |
| 2 |
Jane Street
New York
|
+$103K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$41K |
| 4 |
Renaissance Technologies
New York
|
+$35.9K |
| 5 |
Squarepoint
New York
|
+$29.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$806K |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$343K |
| 3 |
State Street
Boston,
Massachusetts
|
-$300K |
| 4 |
Los Angeles Capital Management
Los Angeles,
California
|
-$255K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$230K |
ALXO Hedge Fund Activity: Q2 2025 in Review
61 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q2 2025, worth a combined $12.6M — down 43% from $22.1M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ALXO and 10 opened new positions — a net loss of 24 holders — while 32 trimmed existing stakes and 9 added.
The largest buyer was Almitas Capital, adding an estimated $598K. The largest seller was BlackRock, cutting an estimated $806K.
- 61 institutional investors held ALX Oncology (ALXO) as of Q2 2025, down from 85 in Q1 2025.
- Funds reported $12.6M of ALX Oncology stock for Q2 2025, down 43% quarter-over-quarter.
- 10 funds opened new ALX Oncology positions in Q2 2025 and 34 closed out, a net change of -24 holders.
- The largest ALX Oncology buyer in Q2 2025 was Almitas Capital, an estimated $598K added.
- The largest ALX Oncology seller in Q2 2025 was BlackRock, an estimated $806K sold.
Based on aggregated 13F filings for Q2 2025.